CASI Pharmaceuticals, Inc. (41) | Business Finance (12)
Browse by Subcategory
Recent Contracts
-
Promissory Note issued by the Registrant to East West Bank, dated May 23, 2022
(Filed With SEC on August 12, 2022)
-
Business Loan Agreement between the Registrant and East West Bank, dated May 23, 2022
(Filed With SEC on August 12, 2022)
-
Commercial Security Agreement between the Registrant and East West Bank, dated May 23, 2022
(Filed With SEC on August 12, 2022)
-
Commercial Pledge Agreement between the Registrant and East West Bank, dated May 23, 2022
(Filed With SEC on August 12, 2022)
-
Common Stock Sales Agreement (the Sales Agreement) by and between CASI Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC dated October 29, 2021
(Filed With SEC on October 29, 2021)
-
Investment Agreement by and between Juventas Cell Therapy Ltd and CASI Biopharmaceuticals (WUXI) Co., Ltd. effective as of September 22, 2020
(Filed With SEC on November 9, 2020)
-
Contract for Assignment of the Right to the Use of the State-owned Construction Land (no. 3202842019CR0019) dated November 15, 2019
(Filed With SEC on March 16, 2020)
-
Description of Common Stock
(Filed With SEC on March 30, 2021)
-
Description of Common Stock
(Filed With SEC on March 16, 2020)
-
Investment Agreement in respect of Juventas Cell Therapy Ltd. executed June 15, 2019
(Filed With SEC on August 9, 2019)
-
Amendment No. 1 to Common Stock Sales Agreement by and between CASI Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC dated July 19, 2019
(Filed With SEC on July 19, 2019)
-
Shareholders Agreement, dated November 16, 2018, between CASI Pharmaceuticals, Inc. and Wuxi Jintou Huicun Investment Enterprise (Limited Partnership)
(Filed With SEC on March 29, 2019)